New patent covers progressive MS drug for patients in US
Immunic Therapeutics will receive a new U.S. patent covering its experimental therapy, vidofludimus calcium, and some related molecules in people with…
Articles by Marisa Wexler, MS
Most MS neurologists in the US have received pharma payments
In the U.S., nearly 4 out of 5 neurologists prescribing therapies for multiple sclerosis (MS) have received payments from…
Study finds potential strategy for myelin repair in MS
Targeting a protein called SOX6 could be an effective way to promote myelin repair in people with multiple sclerosis…
Ketogenic diet shows promise for MS, but more research needed
A ketogenic diet — which involves eating a very low amount of carbohydrates and replacing them with fat — may…
New PET tracer imaging tech could help track nerve fiber loss in MS
A new positron emission tomography (PET) tracer may help determine the extent of nerve fiber loss in multiple sclerosis…
Meds for myelin sheath repair may help limit nerve damage in MS
Medications that can promote the repair of the myelin sheath — the protective coating around nerve cells in the body…
Meta-analysis isolates iron rim lesions as markers of MS severity
A type of imaging finding called iron rim lesions are associated with more severe disability and a greater extent of…
Data: MS cases up worldwide, but disease-related deaths are down
Over the past three decades, the number of adults worldwide being diagnosed with multiple sclerosis (MS) has increased, but…
MS may increase Alzheimer’s risk, new genetic analysis finds
Multiple sclerosis (MS) may increase the risk of developing Alzheimer’s disease, according to a new analysis of genetic…
Fenebrutinib curbs brain lesions in MS, Phase 2 study finds
Fenebrutinib significantly reduced the occurrence of new brain lesions with active inflammation in people with relapsing multiple sclerosis (MS),…
Most MS patients satisfied with botulinum toxin for spasticity
People with multiple sclerosis (MS) who are treated with formulations of botulinum toxin to manage spasticity generally report…
Researchers unlock new way of stopping attack of T-cells in MS
A team of U.S. and Chinese researchers appears to have unlocked a novel way to stop T-cells from attacking the…
Anti-CD20 therapy reshapes immune cell profiles in MS: Study
Anti-CD20 therapies, a type of treatment approved for multiple sclerosis (MS), alter the activity of several types of immune…
Advanced imaging technology may help predict MS brain lesions
A new imaging technology may help detect early signs of brain damage in people with multiple sclerosis (MS) that…
Trial: Vidofludimus calcium shows benefits for 9 of 10 RRMS patients
More than 90% of relapsing-remitting multiple sclerosis (RRMS) patients who received Immunic Therapeutics‘ experimental oral therapy vidofludimus…
3 progressive MS patients see lower disability with CAR T-cell therapy
A CAR T-cell therapy from Iaso Biotherapeutics was tolerated well and led to marked improvements in disability for three…
Brain growth may compensate for damage in benign MS: MRI study
In people with benign relapsing-remitting multiple sclerosis (RRMS) who have minimal disease activity, there is a loss of overall…
Gender-affirming hormone therapy may affect MS disease activity
Hormone therapies used in gender-affirming care for transgender people may affect disease activity in multiple sclerosis (MS), a small…
Children with MS show signs of accelerated biological aging: Study
Children with pediatric-onset multiple sclerosis (POMS) experience biological aging at a faster rate than children without the disease, a…
Childhood infections, stress may increase MS risk: Study
Infections and stressful life events in childhood may increase the risk of developing multiple sclerosis (MS), while childhood exercise…
Signaling molecules impair growth of myelin-making brain cells
Pro-inflammatory signaling molecules that have been implicated in multiple sclerosis (MS) cause problems with the growth and development of…
Childhood adversity tied to greater MS risk; quality of evidence low
People who experience adversity during childhood, such as abuse or neglect, may be at increased risk of multiple sclerosis…
MS risk factor EBV alters the way B-cells move through body: Study
The Epstein-Barr virus (EBV) — a well-established risk factor for multiple sclerosis (MS) — is able to alter…
Tysabri safe as treatment for MS during pregnancy, breastfeeding
Tysabri (natalizumab), an approved treatment for forms of multiple sclerosis (MS), can be safely used during pregnancy or…
Masitinib lowers nerve damage, slows disease progression in mice
Treatment with masitinib, an experimental therapy being developed by AB Science for progressive forms of multiple sclerosis (MS),…
Quantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MS
Quantum Biopharma intends to ask the U.S. Food and Drug Administration (FDA) this year for permission to start a…
Lachnospiraceae bacteria in gut seen as potential MS risk factor
Elevated levels of two bacterial strains from the Lachnospiraceae family in the gut may be a key risk factor for…
FDA approves new generic version of relapsing MS therapy Copaxone
The U.S. Food and Drug Administration (FDA) has approved a new generic form of glatiramer acetate injection, a treatment for…
B-cell levels can predict PIRA risk in relapsing MS patients on Ocrevus
In people with relapsing forms of multiple sclerosis (MS) treated with Ocrevus (ocrelizumab), levels of B-cells can help…
Patients with PIRA have more damage to white matter: Study
People with multiple sclerosis (MS) who experience progression independent of relapse activity (PIRA) tend to have greater damage to…